中国药物警戒 ›› 2026, Vol. 23 ›› Issue (7): 835-840.
DOI: 10.19803/j.1672-8629.20250904

• 综述 • 上一篇    

曲美他嗪药理作用与临床应用研究进展

火鸿敏1, 杨耀芳2,*, 蒋良华1, 毛子贤1, 王晓英1, 胡萍1   

  1. 1上海市闵行区浦江社区卫生服务中心,上海 200112;
    2复旦大学附属上海市第五人民医院,上海 200240
  • 收稿日期:2025-12-12 出版日期:2026-07-15 发布日期:2026-07-16
  • 通讯作者: *杨耀芳,女,硕士,主任药师,临床药理学与药事管理。E-mail:yang.yao.fang@126.com
  • 作者简介:火鸿敏,女,本科,副主任药师,临床药学与安全用药。
  • 基金资助:
    上海市社区卫生协会2024年社区科研项目(SWX24M11); 上海市闵行区医学会科研课题(2025MHYXH26)

Research progress in pharmacological mechanisms and clinical applications of trimetazidine

Huo Hongmin1, Yang Yaofang2,*, Jiang Lianghua1, Mao Zixian1, Wang Xiaoying1, Hu Ping1   

  1. 1Pujiang Community Health Center, Shanghai 200112, China;
    2Shanghai Fifth People’s Hospital, Fudan University, Shanghai 200240, China;
  • Received:2025-12-12 Online:2026-07-15 Published:2026-07-16

摘要: 目的 综述曲美他嗪的药理作用、临床应用、引发帕金森综合征潜在相关风险,为临床安全合理用药提供参考。方法 系统检索近五年曲美他嗪相关实验与临床文献,梳理其药理作用和临床应用,探讨曲美他嗪诱发帕金森综合征的可能相关机制。结果 曲美他嗪具有抗凋亡、调节自噬、调节代谢、抗氧化、抗焦亡、抗炎的药理作用,可用于急性ST段抬高型心肌梗死、慢性心力衰竭、病毒性心肌炎和重症肺炎的治疗,帕金森综合征与自噬功能异常、坏死性凋亡通路、线粒体功能障碍和表观遗传修饰的相关通路有关。结论 综合曲美他嗪的药理作用,在治疗多种疾病及其诱发帕金森综合征的多靶点、多途径作用特点,为后续研究其作用机制与诱发机制的关联性提供参考。

关键词: 曲美他嗪, 凋亡, 自噬, 氧化, 药理, 帕金森综合征

Abstract: Objective To explore the pharmacological effects, clinical applications and association of trimetazidine with Parkinson’s syndrome in order to provide a reference for safe and rational use of the drug. Methods Literature about experiments on and clinical use of trimetazidine in the past five years was retrieved to find out more about the pharmacological effects and clinical applications of trimetazidine. The possible mechanisms through which trimetazidine was involved in Parkinson’s syndrome were explored. Results The latest research found that trimetazidine could deliver anti-apoptosis, antioxidant, anti-pyroptosis and anti-inflammation effects while regulating autophagy and metabolism, suggesting that it could be used in the treatment of acute ST-segment elevation myocardial infarction, chronic heart failure, viral myocarditis and severe pneumonia. Parkinson’s syndrome was linked to autophagy dysfunction, necroptosis pathway, mitochondrial dysfunction, and epigenetic modifications. Conclusion The pharmacological effects of trimetazidine have been summarized. This drug combats a range of diseases while inducing Parkinson’s syndrome through multi-targets and multi-pathways. This study is expected to provide evidence for subsequent studies on the related mechanisms and disease-inducing factors.

Key words: Trimetazidine, Apoptosis, Autophagy, Oxidation, Pharmacology, Parkinson’s Syndrome

中图分类号: